Genetic analysis reveals how Pseudomonas aeruginosa uses an endolytic muramidase to outcompete other bacteria, suggesting a new antibacterial mechanism.
Pseudomonas aeruginosa is an opportunistic pathogen that frequently resides in multispecies communities. During chronic infections, P. aeruginosa employs a diverse arsenal of antibacterial weapons to complete with other bacteria for resources and space. Using genetic and biochemical approaches, we identified a T6SS-dependent antibacterial effector-immunity pair, PseM and PA0990 in P. aeruginosa. Our findings demonstrate that PseM functions as an endolytic muramidase, targeting prey bacteria by hydrolytically cleaving cell-wall peptidoglycan, while its immunity partner PA0990 provides self-protection. The X-ray crystal structure of PseM reveals a homodimeric configuration, with its active site formed by segments from both monomers. Through structural analysis and macromolecular docking simulations, we further elucidate the substrate-binding residues critical for PseM's activity. Importantly, we show that PseM contributes to P. aeruginosa growth among bacterial competition. Together, these results uncover a novel antibacterial mechanism mediated by PseM, highlighting the dynamic nature of inter- and intraspecies competition within bacterial populations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: